Coverage update: 17 September 2026
Compounded medicines may serve a legitimate need when an approved product cannot meet a patient-specific requirement. However, a compounded product is not the same as an FDA-approved medicine and does not undergo the same premarket review for safety, effectiveness and manufacturing quality.
Key safety concerns
- Incorrect strength or concentration
- Contamination or sterility failure
- Stability and storage problems
- Labelling or calculation errors
- Use when an appropriate approved product is available
What clinicians should verify
Clarify the clinical reason for compounding, formulation, concentration, route, storage, beyond-use information and the accountable pharmacy or facility. Medication reconciliation should distinguish an approved branded/generic product from a compounded preparation.
Limitations and India relevance
FDA communications describe the United States regulatory system. They do not automatically determine the legal or regulatory status of a product in India. Indian procurement and use must follow CDSCO, State Drug Controller, institutional pharmacy and applicable legal requirements.
Official sources
Related articles
Featured image: Roberto Sorin via Unsplash.
Last reviewed: 19 September 2026
Medical disclaimer: This article is for professional education and news interpretation only. It does not replace patient-specific assessment, local protocols, prescribing information or specialist advice.